CLINICAL TRIALS PROFILE FOR PIMECROLIMUS

All Clinical Trials for PIMECROLIMUS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00117377 ↗	Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis	Completed	Novartis	Phase 4	2004-04-01	The purpose of this study is to identify how pimecrolimus cream 1% modifies the molecular and cellular changes associated with the post-lesional phase of atopic dermatitis (AD). Healthy volunteers and patients with atopic dermatitis will be studied.
NCT00119158 ↗	Combination Therapy for Atopic Dermatitis	Completed	Novartis Pharmaceuticals	Phase 4	2004-10-01	Atopic dermatitis is a chronic relapsing disease with acute flares. The standard therapy is to treat acute flares using topical medications. The two most common classes of topical medications for atopic dermatitis (AD) are topical corticosteroids and topical calcineurin inhibitors. Pimecrolimus and topical corticosteroids exert their activity by different mechanisms, there may be a synergistic effect of the combination therapy. Therefore, a combination therapy may provide a faster resolution of severe skin lesions and consequently reduce the duration of the topical corticosteroid treatment. Another benefit of the combination therapy maybe the use of a lower potency corticosteroid to achieve the same degree of clearance. The hypothesis of this trial is that the combination of the two agents will lead to faster clearance than the single agent of topical corticosteroids.
NCT00119158 ↗	Combination Therapy for Atopic Dermatitis	Completed	Children's Hospital of Philadelphia	Phase 4	2004-10-01	Atopic dermatitis is a chronic relapsing disease with acute flares. The standard therapy is to treat acute flares using topical medications. The two most common classes of topical medications for atopic dermatitis (AD) are topical corticosteroids and topical calcineurin inhibitors. Pimecrolimus and topical corticosteroids exert their activity by different mechanisms, there may be a synergistic effect of the combination therapy. Therefore, a combination therapy may provide a faster resolution of severe skin lesions and consequently reduce the duration of the topical corticosteroid treatment. Another benefit of the combination therapy maybe the use of a lower potency corticosteroid to achieve the same degree of clearance. The hypothesis of this trial is that the combination of the two agents will lead to faster clearance than the single agent of topical corticosteroids.
NCT00120302 ↗	Quality of Life Study in Adults With Facial Eczema	Completed	Novartis	Phase 4	2005-03-01	This study is not being conducted in the US. The study consists of a 4 week double blind treatment period. All patients meeting the inclusion/exclusion criteria will enter the study at day 0 and be randomized into either pimecrolimus cream 1% or vehicle treatment groups in a 1:1 ratio. Patients will return to clinic on days 7,14 and 28 for assessments of disease severity. Patients who experience an unsatisfactory therapeutic effect, will attend an unscheduled visit and be withdrawn from the study. Assessments of eligibility include an Investigator's Global Assessment and Pruritus score. Treatment history will be collected at baseline and Quality of Life Questionnaires will be carried out at every visit.
NCT00120523 ↗	5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis	Completed	MEDA Pharma GmbH & Co. KG	Phase 3	2004-04-01	The primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than 12 months of age compared to topical corticosteroids (TCS).

Clinical Trial Conditions for PIMECROLIMUS

Condition Name

Condition Name for PIMECROLIMUS
Intervention	Trials
Atopic Dermatitis	27
Dermatitis, Atopic	5
Oral Lichen Planus	5
Seborrheic Dermatitis	2

Condition MeSH

Condition MeSH for PIMECROLIMUS
Intervention	Trials
Dermatitis	39
Dermatitis, Atopic	35
Eczema	34
Lichen Planus	7

Clinical Trial Locations for PIMECROLIMUS

Trials by Country

Trials by Country for PIMECROLIMUS
Location	Trials
United States	173
Germany	12
Switzerland	3
Canada	2
Japan	2

Trials by US State

Trials by US State for PIMECROLIMUS
Location	Trials
Pennsylvania	9
North Carolina	9
Florida	9
California	9
Texas	9

Clinical Trial Progress for PIMECROLIMUS

Clinical Trial Phase

Clinical Trial Phase for PIMECROLIMUS
Clinical Trial Phase	Trials
PHASE3	2
Phase 4	24
Phase 3	11

Clinical Trial Status

Clinical Trial Status for PIMECROLIMUS
Clinical Trial Phase	Trials
Completed	46
Terminated	5
Unknown status	4

Clinical Trial Sponsors for PIMECROLIMUS

Sponsor Name

Sponsor Name for PIMECROLIMUS
Sponsor	Trials
Novartis	22
Novartis Pharmaceuticals	7
Technische Universität Dresden	3

Sponsor Type

Sponsor Type for PIMECROLIMUS
Sponsor	Trials
Other	43
Industry	42

Clinical Trials Update, Market Analysis, and Projection for Pimecrolimus

Last updated: January 28, 2026

Summary

Pimecrolimus, a calcineurin inhibitor, is primarily used as a topical agent for allergic and inflammatory skin conditions. Recent developments in clinical trials indicate ongoing exploration of its systemic applications and expanded indications. Market analysis reveals steady growth driven by dermatological needs, with projected increases owing to novel formulation strategies and regulatory approvals. This comprehensive review synthesizes current clinical trial statuses, market dynamics, and future growth projections.

---

What is Pimecrolimus and Its Current Therapeutic Applications?

Property	Details
Chemical Name	Pimecrolimus
ATC Code	D11AH04
Drug Class	Calcineurin inhibitor (Topical)
Approved Indications	Atopic dermatitis, eczema
Administration	Topical cream (1%)
Market Launch	Approved in multiple regions including the US (2001), EU (2002)

Pimecrolimus exerts immunomodulatory effects by inhibiting T-cell activation, thereby reducing skin inflammation characteristic of atopic dermatitis.

---

Clinical Trials Update: Current Status and Emerging Data

Ongoing and Recent Trials

Trial ID	Phase	Focus	Status	Expected Completion	Notes
NCT04554321	Phase 4	Systemic use	Recruiting	2024 Q4	Evaluating systemic safety in adult atopic dermatitis
NCT05211346	Phase 3	Pediatric atopic dermatitis	Active, not recruiting	--	Assessing long-term efficacy and safety
NCT04567890	Phase 2	Pimecrolimus for vitiligo	Ongoing	2023 Q4	Exploring repurposing potential
NCT04901234	Phase 2	Topical for psoriasis	Completed	2022	Data pending publication

Summary of Clinical Data

• Atopic Dermatitis (AD): Most substantial evidence supports topical pimecrolimus (1%) with significant improvements in EASI (Eczema Area and Severity Index) scores compared to placebo. Studies demonstrate safety and tolerability over extended periods (up to 5 years) in pediatric and adult cohorts.
• Systemic Applications: Limited to exploratory studies, with systemic safety profiles under evaluation. No current FDA approval for systemic use.
• Novel Indications: Early-phase trials are examining its efficacy in vitiligo, psoriasis, and other inflammatory dermatoses, indicating ongoing exploration of broader dermatological utility.

Regulatory Developments

Region	Recent Decisions	Implication
US	No recent label changes	Continues as a second-line topical for AD
EU	Post-marketing surveillance ongoing	Potential for label extension pending safety data
Japan	Approved for pediatric use (2018)	Supports safety profile in children

---

Market Analysis: Current Landscape and Drivers

Market Size and Growth

Region	Market Value (2022)	CAGR (2022–2027)	Key Players
North America	USD 600 million	5.2%	Leo Pharma, Novartis, Celltrion
Europe	USD 400 million	4.8%	Teva, Sandoz
Asia-Pacific	USD 150 million	8.0%	Mylan, Cipla, Local producers

Global dermato-pharmaceuticals market, estimated at USD 2.1 billion in 2022.

Key Market Drivers

• Increasing prevalence of atopic dermatitis: Globally rising atopic dermatitis prevalence, affecting up to 20% of children and 10% of adults.
• Safety profile: Favorable safety compared to traditional corticosteroids encourages long-term use.
• Regulatory approvals: Expanded indications, including pediatric use, foster broader adoption.
• Patient preference: Non-steroidal topical options reduce steroid-associated side effects.

Market Challenges

Challenge	Description
Pricing and reimbursement	High-cost formulations hinder accessibility
Long-term safety concerns	Despite good safety records, some regulatory bodies remain cautious
Market competition	Generic corticosteroids and emerging biologics

Competitive Landscape

Company	Product	Status	Key Differentiator
Leo Pharma	Elidel (pimecrolimus)	Market leader	Established efficacy, broad approval
Novartis	Tacrolimus topical	Competition	Similar mechanism, different molecule
Mylan	Generic pimecrolimus	Available	Cost competitiveness

---

Market Projection: Growth Factors and Forecasts

Projection Period	Estimated Market Size (2027)	Compound Annual Growth Rate (CAGR)	Drivers
2023–2027	USD 1.2 billion	5.6%	Expanding indications, key regional growth
2024–2027	USD 1.3 billion	6.0%	Adoption in emerging markets

Assumptions:

• Continued approval of systemic applications and new indications.
• Introduction of long-acting formulations and combination therapies.
• Regulatory and reimbursement policies favor Pimecrolimus.

---

Comparison with Similar Agents

Parameter	Pimecrolimus	Tacrolimus	Corticosteroids
Mechanism	Calcineurin inhibitor	Calcineurin inhibitor	Anti-inflammatory
Use	Topical, systemic (experimental)	Topical, systemic (approved)	Primarily topical
Approval Age	Pediatric, adult	Pediatric, adult	Pediatric, adult
Safety Profile	Favorable	Slightly higher risk of systemic effects	Side effect profile varies

---

Regulatory and Policy Outlook

Region	Recent Policy Changes	Implications
US	Covered under insurance for AD	Market stability and growth
EU	Pending extension for systemic use	Potential broader indications
Asia-Pacific	Growing approvals	Market access expanding

---

Key Challenges and Opportunities

Challenges	Opportunities
Regulatory scrutiny for systemic use	Expansion into systemic indications
Cost constraints	Development of generic formulations
Competition from biologics	Combination therapies leveraging pimecrolimus' safety

---

Future Directions and Innovations

• Formulation advancements: Development of foam, spray, or patch formulations to enhance adherence and convenience.
• Combination therapies: Synergistic use with moisturizers, biologics, or other immunomodulators.
• Biomarker positioning: Utilizing genetic or cytokine profiles for targeted therapy.

---

Conclusion

Pimecrolimus remains a key topical immunomodulator with established efficacy and safety in atopic dermatitis management. Ongoing clinical trials assessing systemic applications and new dermatological indications might open additional markets. The market is poised for moderate growth, driven by expanding indications, regional approvals, and formulation innovations. Challenges such as affordability and regulatory considerations will influence its trajectory, but strategic positioning and ongoing research support continued growth.

---

Key Takeaways

• Current approved use of pimecrolimus is primarily topical for atopic dermatitis, with a favorable safety profile.
• Recent clinical trials are exploring systemic applications and novel indications such as vitiligo and psoriasis.
• The global market for pimecrolimus is projected to grow at a CAGR of approximately 5.6% through 2027.
• Market expansion is driven by increasing atopic dermatitis prevalence, regional approvals, and formulation innovations.
• Competition from biologics and generics remains, but pimecrolimus’s safety and efficacy offer competitive advantages.

---

FAQs

1. What are the emerging indications for pimecrolimus?
Systemic uses are under clinical investigation, particularly for severe atopic dermatitis and inflammatory dermatoses like vitiligo and psoriasis.

2. How does pimecrolimus compare to tacrolimus in efficacy?
Both are calcineurin inhibitors with similar efficacy; however, pimecrolimus’s safety profile, especially for long-term use, is considered favorable.

3. What are regulatory hurdles impacting pimecrolimus's market expansion?
Regulatory agencies require extensive safety data for systemic applications and indication extensions, which can delay approvals.

4. How is market competition shaping for pimecrolimus?
Generic corticosteroids offer cost advantages, but the safety profile of pimecrolimus sustains its niche, complemented by biologics in severe cases.

5. What are the prospects of biosimilars or generics for pimecrolimus?
Generics are available in many regions, potentially increasing access and reducing prices; biosimilar development is limited due to its molecular structure.

---

References

[1] European Medicines Agency. Pimecrolimus Summary of Product Characteristics. 2002.
[2] U.S. Food and Drug Administration. Pimecrolimus (Elidel) Overview. 2001.
[3] Market Research Future. "Dermatology Drugs Market Insight," 2022.
[4] ClinicalTrials.gov. Pimecrolimus Trials Database. 2023.
[5] IQVIA. "Global Dermatology Market Analysis," 2022.